Reduce release delays caused by fragmented GMP investigations. Causix helps pharma manufacturers investigate deviations faster, reuse prior site learning, and improve release-flow visibility across regulated manufacturing environments.
Every GMP deviation investigation requires information from multiple systems, documents and subject matter experts.
Investigation teams spend valuable time searching historical deviations, reviewing prior CAPAs, cross-checking SOPs, collecting batch context and aligning multiple stakeholders.
Batches remain unavailable while investigations continue.
Product availability may be affected.
Quality, production, validation and SMEs reconnect fragmented information.
Prior learning is difficult to find and reuse.
Leadership visibility often arrives too late.
Causix supports investigators with workflow-specific decision intelligence.
Find relevant historical deviations without manual searching.
Understand what actions were taken previously and how they performed.
Support product quality, patient safety, data integrity, validation, regulatory impact and release-risk assessment.
Give site and quality leaders visibility into investigation pressure, blocked cases and recurring risk patterns.
The pilot MVP connects historical deviation review, linked action context and portfolio-level pattern visibility in one investigator-facing workspace.
Technical equipment deviations, prior corrective actions and similar cases presented together for evidence-led review.
Review deviation volume, leading topics and root-cause classifications before drilling into a case.
Illustrative pilot view of investigation pressure, batches on hold and priority release-risk signals.
Investigator and historical pattern views are translated presentations of source-language records. Leadership visibility is an illustrative pilot view. Recommendations remain subject to expert review.
Causix strengthens investigation workflows without replacing human judgment.
In parallel, site and quality leaders can track:
Causix is designed specifically for regulated pharmaceutical environments. Human approval remains mandatory.
The goal is better decisions - not replacing GMP expertise.
Most AI startups begin with technology. Causix began with a workflow problem.
Across years working with manufacturing performance, batch release flow, operational excellence and digital transformation, the same pattern kept appearing: the information existed, the knowledge existed and the experts existed. Decisions were delayed because information was fragmented.
Causix was created to help teams spend less time searching and more time deciding.
Causix combines deep operational domain experience with pharma business development support for the first pilot phase.
Causix is founded by someone who has lived the workflow problem.
LinkedIn profile
Additional technical and implementation support is engaged during pilot preparation.
We are currently engaging with selected pharma and biotech organizations for pilot discussions.
We are currently seeking a limited number of pilot partners within regulated manufacturing environments.
contact@causix.ai
+45 50 28 88 03
Greater Copenhagen, Denmark